| Vol. 15.01 – 12 January, 2023 |
| |
|
|
| Researchers showed that deletion of the epigenetic regulator MLL3, a tumor suppressor frequently altered in human cancer, promoted the acquisition of hybrid epithelial–mesenchymal transition in breast cancer cells. [Nature Cell Biology] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists discovered that therapeutic response to immune checkpoint inhibitor plus paclitaxel was associated with subcellular redistribution of PD-L1. [Cell Research] |
|
|
|
| The authors identified the membrane-associated protein Annexin A1 as an interactor of leucine-glycine-asparagine repeat protein in mammary epithelial cells. [Nature Communications] |
|
|
|
| Through various transplantation studies in mice, investigators showed that cancer-associated fibroblasts (CAFs) in both invasive lobular breast cancer and TNBC originated from mammary tissue-resident normal fibroblasts. [Nature Communications] |
|
|
|
| Scientists reported an epigenetic pliancy mechanism that allowed cancer cells to successfully metastasize. [Science Advances] |
|
|
|
| Researchers reported that the elevation of CD73 levels due to its aberrant turnover was correlated with poor prognosis in immune-cold TNBCs. [Science Advances] |
|
|
|
| The authors developed 3D computational models, which hypothesized that leader cells needed to generate high protrusive forces and overcome extracellular matrix resistance at the leading edge. [Developmental Cell] |
|
|
|
| Investigators cultured primary organoids from a basal-TNBC genetically engineered mouse model in 3D collagen gels to characterize their invasive behavior. [Oncogene] |
|
|
|
| Researchers demonstrated that RAC1B, the only known alternatively spliced variant of the small GTPase RAC1, was expressed in a subset of breast CSCs (BCSCs) in vivo and its function was required for the maintenance of BCSCs and their chemoresistance to doxorubicin. [Oncogene] |
|
|
|
| Scientists demonstrated that FAK inhibitors could reverse breast cancer metastasis induced by upregulation of NEDD9 via pan-histone deacetylase inhibitors, which might offer a potential combination therapy for breast cancer. [Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators formulated inorganic carbonate apatite nanoparticles to carry and deliver the purified breast cancer type 1/2 (BRCA1/2) gene-bearing plasmid DNA both in vitro and in vivo. [Scientific Reports] |
| |
|
|
|
| The authors discuss microRNAs, cytokines, extracellular vesicles, as well as transcription factors and immune checkpoints, that influence Treg/IL-17–producing Treg/Th17 cell axis in breast cancer. [Molecular Therapy Oncolytics] |
|
|
|
|
| The Research Institute of the McGill University Health Centre (RI-MUHC) announced the initiation of a new randomized Phase III clinical trial, TROPION-Breast03, to test the efficacy of datopotamab deruxtecan with or without durvalumab as an adjuvant therapy for patients with Stage I-III TNBC. [McGill University Health Centre] |
|
|
|
| Treadwell Therapeutics announced that the US FDA has granted Fast Track Designation to CFI-402257 for the treatment of adult patients with ER+/HER2– advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, both as a monotherapy and in combination with fulvestrant. [Treadwell Therapeutics] |
|
|
|
|
| May 11 – 13, 2023 Berlin, Germany |
|
|
|
|
|
| Pompeu Fabra University – Barcelona, Spain |
|
|
|
| Stanford Medicine – Stanford, California, United States |
|
|
|
| Toulouse Cancer Research Center – Toulouse, France |
|
|
|
| University Medical Center Freiburg – Freiburg, Germany |
|
|
|
| UTHSC-Houston – Houston, Texas, United States |
|
|
|
|